Delivery Order SPE2DP20D0002-SPE2DP25F0860

Award Date 11/14/24
Potential Completion Date 11/19/24
Potential Value $318K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
  • SPE2DP20D0002
    Indefinite Delivery Contract
  • SPE2DP20D0002-SPE2DP25F0860
    Delivery Order

This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. The contract has a ceiling value of $317,609.46 and a period of performance through November 19, 2024. The award is unrestricted, meaning Teva competed as a large business without any set-aside designations. Teva is a major pharmaceutical supplier to federal agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons, and Indian Health Service, and has received numerous federal contract awards for the delivery of critical pharmaceutical products such as vaccines, antiviral medications, and treatments for conditions like multiple sclerosis. This contract supports military immunization programs and is part of Teva's role in maintaining reliable access to essential medications for federal healthcare programs through long-term, large-scale contracts, including Indefinite Delivery Contracts (IDCs) with the VA and DLA.

Generated 2/13/25, 9:32 AM